Skip to main content
SpringerLink
Log in

Potential Antifibrotic Therapies: Approaching the Bedside: Proof-of-Concept Studies (Part 1)

  • Conference paper
Portal Hypertension VI

  • 1056 Accesses

Abstract

Progressive hepatic fibrosis in combination with nodular regeneration dominates the increased intrahepatic vascular resistance to portal flow and thus portal hypertensive syndrome (PHT), which is one of the major driving forces in the development of clinical complications associated with cirrhosis. From this perspective, attempts to prevent, halt, or reverse liver fibrosis have logically been pursued for decades. At present, successful antiviral treatment serves as the best example for antifibrotic strategies and has encouraged the interest herein given the clinical trade-off of improved clinical outcomes, reduced portal pressure, and decreased all-cause mortality. This chapter serves the purpose of briefly pointing out some of the most far-advanced molecules, including FXR agonists, anticoagulation, angiotensin blockage, and modulating dysbiosis, in their transition from the bench to the bedside.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bosch J, García-Pagán JC (2000) Complications of cirrhosis. I. Portal hypertension. J Hepatol 32(1 Suppl):141–156

    Article  CAS  PubMed  Google Scholar 

  2. Laleman W, Landeghem L, Wilmer A, Fevery J, Nevens F (2005) Portal hypertension: from pathophysiology to clinical practice. Liver Int 25:1079–1090

    Article  CAS  PubMed  Google Scholar 

  3. Lee YA, Wallace MC, Friedman SL (2015) Pathobiology of liver fibrosis: a translational success story. Gut 64(5):830–841

    Google Scholar 

  4. Mehal WZ, Iredale J, Friedman SL (2011) Scraping fibrosis: expressway to the core of fibrosis. Nat Med 17:552–553

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Torok N, Dranoff JA, Schuppan D, Friedman SL (2015) Strategies and endpoints of antifibrotic drug trials: summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology 62(2):627–634

    Google Scholar 

  6. Karsdal MA, Manon-Jensen T, Genovese F et al (2015) Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 308(10):G807–G830

    Google Scholar 

  7. Marcellin P, Gane E, Buti M et al (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381:468–475

    Article  CAS  PubMed  Google Scholar 

  8. D’Ambrosio R, Aghemo A, Rumi MG et al (2012) A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 56:532–543

    Article  PubMed  Google Scholar 

  9. Lefebvre P, Cariou B, Lien F et al (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 89:147–191

    Article  CAS  PubMed  Google Scholar 

  10. Pellicciari R, Costantino G, Camaioni E et al (2004) Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem 47:4559–4569

    Article  CAS  PubMed  Google Scholar 

  11. Fan M, Wang X, Xu G et al (1849) Bile acid signaling and liver regeneration. Biochim Biophys Acta 2015:196–200

    Google Scholar 

  12. Wang YD, Chen WD, Wang M et al (2008) Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48:1632–1643

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wolfe A, Thomas A, Edwards G et al (2011) Increased activation of the Wnt/beta-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther 388:12–21

    Article  Google Scholar 

  14. Verbeke L, Farre R, Trebicka J et al (2014) Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59:2286–2298

    Article  CAS  PubMed  Google Scholar 

  15. Lutz P, Berger C, Langhans B et al (2014) A farnesoid X receptor polymorphism predisposes to spontaneous bacterial peritonitis. Dig Liver Dis 46:1047–1050

    Article  CAS  PubMed  Google Scholar 

  16. Fickert P, Fuchsbichler A, Moustafa T et al (2009) Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol 175:2392–2405

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Fiorucci S, Antonelli E, Rizzo B et al (2004) The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127:1497–1512

    Google Scholar 

  18. Albanis E, Alvarez CE, Pruzansky M et al (2005) INT-747, a novel FXR activator, reverses hepatic fibrosis and cirrhosis in thioacetamide-induced liver injury in rats. Hepatology 42(4, Suppl 1):1040

    Google Scholar 

  19. Verbeke L, Mannaerts I, Schierwagen R et al (2015) Obeticholic acid, a farnesoid X-receptor agonist, reduces hepatic fibrosis in a rat model of toxic cirrhosis. J Hepatol 2015; Suppl 2: 62: P0445

    Google Scholar 

  20. Fiorucci S, Antonelli E, Rizzo B et al (2005) A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 314:584–595

    Google Scholar 

  21. Verbeke L, Farre R, Verbinnen B et al (2015) The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am J Pathol 185:409–419

    Article  CAS  PubMed  Google Scholar 

  22. Ubeda M, Borrero MJ, Lario M et al (2014) The Farnesoid X receptor agonist, obeticholic acid, improves intestinal antibacterial defense and reduces gut bacterial translocation and hepatic fibrogenesis in CCl4 cirrhotic rats with ascites. J Hepatol 60(Suppl):S63

    Article  Google Scholar 

  23. Hirschfield GM, Mason A, Luketic V et al (2014) Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148:751–761

    Google Scholar 

  24. Neuschwander-Ttri BA, Loomba R, Sanyal AJ, on behalf of NASH Clinical Research Network et al (2015) Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385:956–965

    Article  Google Scholar 

  25. Mookerje R, Rosselli M, Pieri G et al (2014) Effects of the FXR agonist obeticholic acid on hepatic venous pressure gradient in alcoholic cirrhosis: a proof of concept phase 2A study. J Hepatol 60(Suppl):S7

    Article  Google Scholar 

  26. Pares A, Caballeria L, Rodes J (2006) Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 130:715–720

    Article  CAS  PubMed  Google Scholar 

  27. Lisman T, Caldwell SH, Burroughs AK, Northup PG, Senzolo M, Stravitz RT et al (2010) Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 53:362–371

    Article  PubMed  Google Scholar 

  28. Wanless IR, Wong F, Blendis LM et al (1995) Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 21:1238–1247

    CAS  PubMed  Google Scholar 

  29. Wright M, Goldin R, Hellier S et al (2003) Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 52:1206–1210

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Papatheodoridis GV, Papakonstantinou E, Andrioti E et al (2003) Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut 52:404–409

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Yee TT, Griffioen A, Sabin CA et al (2000) The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 47:845–851

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Fiorucci S, Antonelli E, Distrutti E et al (2004) PAR1 antagonism protects against experimental liver fibrosis. role of proteinase receptors in stellate cell activation. Hepatology 39:365–375

    Article  CAS  PubMed  Google Scholar 

  33. Marra F, DeFranco R, Grappone C et al (1998) Expression of the thrombin receptor in human liver: up-regulation during acute and chronic injury. Hepatology 27:462–471

    Article  CAS  PubMed  Google Scholar 

  34. Friedman SL (2003) Liver fibrosis — from bench to bedside. J Hepatol 38(Suppl 1):S38–S53

    Article  PubMed  Google Scholar 

  35. Villa E, Camma C, Marietta M et al (2012) Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143:1253–1260

    Article  CAS  PubMed  Google Scholar 

  36. Dhar A, Tschotazis E, Brown R et al (2015) Warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C): results at one year. J Hepatol 2015; Suppl 2: 62: LP11

    Google Scholar 

  37. Arroyo V, Bosch J, Mauri M et al (1981) Effects of angiotensin II blockade on systemic and hepatic hemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest 11:221–229

    Article  CAS  PubMed  Google Scholar 

  38. Tandon P, Abraldes JG, Berzigotti A et al (2010) Renin-angiotensin-aldosterone inhibitors in the reductio of portal pressure: a systematic review and meta-analysis. J Hepatol 53:273–282

    Article  CAS  PubMed  Google Scholar 

  39. Bataller R, Gines P, Lora J et al (2001) Evidence for a local renin-angiotensin system in human liver: expression in activated hepatic stellate cells. Hepatology 34:399A

    Google Scholar 

  40. Bataller R, Schwabe RF, Choi YH et al (2003) NADPH oxidase signal trans- duces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112:383–394

    Article  Google Scholar 

  41. Colmenero J, Bataller R, Sancho-Bru P et al (2009) Effects of losartan on hepatic expression of non-phagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol 297:G726–G734

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Kim MY, Cho MY, Baik SK et al (2012) Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis – a randomized open-label controlled study. Liver Int 32:977–987

    Article  CAS  PubMed  Google Scholar 

  43. Hidaka H, Nakazawa T, Shibuya A et al (2011) Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial. J Gastroenterol 46:1316–1323

    Article  CAS  PubMed  Google Scholar 

  44. Debernardi-Venon W, Martini S, Biasi F et al (2007) AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol 46:1026–1033

    Article  CAS  PubMed  Google Scholar 

  45. Corey KE, Shah N, Misdraji J et al (2009) The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int 29:748–753

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Abu Dayyeh BK, Yang M, Dienstag JL et al (2011) The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort. Dig Dis Sci 56:564–568

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. van Beuge MM, Prakash J, Lacombe M et al (2011) Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice. J Pharmacol Exp Ther 337:628–635

    Article  PubMed  Google Scholar 

  48. Klein S, van Beuge M, Granzow M et al (2012) Inhibition or Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. J Hepatol 57:1220–1227

    Article  CAS  PubMed  Google Scholar 

  49. Granzow M, Schierwagen R, Klein S et al (2014) Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology 60:334–348

    Article  CAS  PubMed  Google Scholar 

  50. Chassaing B, Etienne-Mesmin L, Gewirtz A (2014) Microbiota-liver axis in hepatic disease. Hepatology 59:328–339

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Dhiman RK, Rana B, Agrawal S et al (2014) Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 147:1327–1337

    Article  CAS  PubMed  Google Scholar 

  52. Vlachogiannakos J, Viazis N, Vasianopoulou P et al (2013) Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 28:450–455

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Liver and Biliopancreatic Disorders, University Hospitals Leuven, KU Leuven, Herestraat 49, Leuven, 3000, Belgium

    Wim Laleman MD, PhD

Authors
  1. Wim Laleman MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wim Laleman MD, PhD .

Editor information

Editors and Affiliations

  1. Gastroenterology Unit, Luigi Sacco University Hospital, Milan, Italy

    Roberto de Franchis

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this paper

Cite this paper

Laleman, W. (2016). Potential Antifibrotic Therapies: Approaching the Bedside: Proof-of-Concept Studies (Part 1). In: de Franchis, R. (eds) Portal Hypertension VI. Springer, Cham. https://doi.org/10.1007/978-3-319-23018-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-23018-4_15

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-23017-7

  • Online ISBN: 978-3-319-23018-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation